AKTS
Aktis Oncology, Inc. NASDAQ Listed Jan 9, 2026$27.01
Pre-mkt
$25.01
-7.40%
Mkt Cap $1.4B
52w Low $15.19
100.0% of range
52w High $27.01
50d MA $20.05
200d MA $19.55
P/E (TTM)
-22.7x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.1x
ROE
—
P/FCF
-19.2x
RSI (14)
74.40
ATR (14)
$1.80
Beta
0.00
50d MA
$20.05
200d MA
$19.55
Avg Volume
241.1K
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
17 Drydock Avenue · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | AMC | -0.31 | -0.38 | -22.6% | 18.27 | +0.3% | +8.0% | -1.0% | -0.2% | +0.3% | -4.8% | — |
| Mar 30, 2026 | AMC | -21.59 | -18.19 | +15.8% | 16.54 | +4.1% | +8.2% | -4.6% | +1.8% | -5.8% | +2.1% | — |
| Feb 25, 2026 | AMC | — | -60.17 | — | 19.50 | +1.5% | +0.7% | +2.5% | -0.6% | +1.1% | +3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16 | Raymond James | Initiates | Strong Buy | $40 | $20.69 | $21.45 | +3.7% | +9.4% | +4.0% | +2.4% | +2.9% | +9.0% |
| Apr 29 | William Blair | Initiates | Outperform | — | $18.60 | $18.72 | +0.6% | +0.6% | +0.2% | +3.6% | -2.2% | +2.3% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.54 | $17.21 | +4.1% | +8.2% | -4.6% | +1.8% | -5.8% | +2.1% |
| Jan 4 | Piper Sandler | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Sep 7 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Sep 7 | B. Riley Securities | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 9 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 15 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Sep 13 | Piper Sandler | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| May 3 | Piper Sandler | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Nov 2 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 4 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jan 4 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 20 | Northland Capital Markets | Maintains | Market Perform → Market Perform | — | — | — | — | — | — | — | — | — |
| Sep 18 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Jul 10 | Northland Capital Markets | Upgrade | Market Perform → Outperform | — | — | — | — | — | — | — | — | — |
| Feb 5 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 2.02
!! High
Aktis Oncology, Inc. -- 8-K 2.02: Earnings Results
Aktis Oncology reported Q1 2026 financial results, with the company releasing earnings highlights and operational updates for the quarter ending March 31, 2026.
May 11
8-K
Unknown — 8-K Filing
A highly experienced pharma executive with deep clinical development expertise at Novartis and AstraZeneca joined Akoustis Technologies, suggesting potential acceleration in regulatory strategy and product development execution for this medical device company.
Apr 16
8-K
Unknown — 8-K Filing
Akoustis' IND clearance for AKY-2519 Phase 1b trial removes regulatory hurdles and validates the radiopharmaceutical candidate's potential, likely attracting investor interest despite clinical-stage risk.
Mar 30
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Mpm Bioimpact Llc | 4,835,872 | $87M | New | Mar 2026 |
| 2 | Blue Owl Capital Holdings Lp | 3,161,348 | $57M | New | Mar 2026 |
| 3 | Rtw Investments, Lp | 1,592,043 | $28M | New | Mar 2026 |
| 4 | Janus Henderson Group Plc | 1,454,267 | $26M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 833,913 | $15M | New | Mar 2026 |
| 6 | Avidity Partners Management Lp | 468,566 | $8M | New | Mar 2026 |
| 7 | Fmr Llc | 386,379 | $7M | New | Mar 2026 |
| 8 | Ubs Group Ag | 353,263 | $6M | New | Mar 2026 |
| 9 | Alyeska Investment Group, L.p. | 290,000 | $5M | New | Mar 2026 |
| 10 | Northern Trust Corp | 149,476 | $3M | New | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 120,322 | $2M | New | Mar 2026 |
| 12 | Soros Fund Management Llc | 100,000 | $2M | New | Mar 2026 |
| 13 | Woodline Partners Lp | 100,000 | $2M | New | Mar 2026 |
| 14 | Citadel Advisors Llc | 75,000 | $1M | New | Mar 2026 |
| 15 | Bank Of America Corp /de/ | 69,926 | $1M | New | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 42,901 | $767K | New | Mar 2026 |
| 17 | Nuveen, Llc | 24,468 | $438K | New | Mar 2026 |
| 18 | D.e. Shaw & Co | 17,062 | $305K | New | Mar 2026 |
| 19 | Universal- Beteiligungs- Und Servicegesellschaft Mbh | 14,185 | $254K | New | Mar 2026 |
| 20 | Invesco Ltd. | 12,113 | $217K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.42B
Enterprise Value
$1.19B
P/E (TTM)
-22.70x
Forward P/E
—
PEG Ratio
3.32x
P/B
—
P/S
218.35x
P/FCF
-19.25x
EV/EBITDA
—
Shares Out
52.5M
Financials (TTM)
Revenue
$6.5M
Net Income
-$63.7M
EBITDA
-$72.4M
Free Cash Flow
-$73.7M
Op Cash Flow
-$64.1M
EPS Basic
$-1.19
EPS Diluted
$-1.19
EPS Forward
$-1.39
Gross Margin
100.0%
Op Margin
-1149.5%
Net Margin
-980.9%
Balance Sheet
Total Assets
$264.9M
Total Liab.
$411.0M
Total Equity
-$146.1M
Cash
$226.8M
LT Debt
$0
Book Value/Sh
$-2.78
Debt/Equity
-0.08x
Current Ratio
7.37
Quick Ratio
7.37
Returns & Growth
ROE
—
ROA
—
ROIC
-31.8%
Rev Growth YoY
+336.9%
EPS Growth YoY
+5.6%
Price Returns
2W
+6.4%
1M
+10.6%
3M
+3.0%
6M
-7.4%
12M
-7.4%
Technicals
52W High
$27.01
52W Low
$15.19
50d MA
$20.05
200d MA
$19.55
RSI (14)
74.40
ATR (14)
$1.80
Beta
0.00
Avg Volume
241K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$30.50
High
$31.00
Low
$30.00
Median
$30.50
Data updated apr 24, 2026 5:06pm
· Source: financialmodelingprep.com